Q1 2024 13F Holders as of 3/31/2024
-
Type / Class
-
Equity / Common Stock, no par value
-
Shares outstanding
-
3.37M
-
Number of holders
-
15
-
Total 13F shares, excl. options
-
1.07M
-
Shares change
-
+813
-
Total reported value, excl. options
-
$3.42M
-
Value change
-
+$2.57K
-
Number of buys
-
5
-
Number of sells
-
-2
-
Price
-
$3.20
Significant Holders of Cyclerion Therapeutics, Inc. - Common Stock, no par value (CYCN) as of Q1 2024
17 filings reported holding CYCN - Cyclerion Therapeutics, Inc. - Common Stock, no par value as of Q1 2024.
Cyclerion Therapeutics, Inc. - Common Stock, no par value (CYCN) has 15 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 1.07M shares
of 3.37M outstanding shares and own 31.79% of the company stock.
Largest 10 shareholders include Slate Path Capital LP (358K shares), MFN Partners Management, LP (169K shares), TYNDALL CAPITAL PARTNERS L P (165K shares), FMR LLC (162K shares), Artal Group S.A. (139K shares), GEODE CAPITAL MANAGEMENT, LLC (32.1K shares), VANGUARD GROUP INC (23.5K shares), BlackRock Inc. (17.2K shares), UBS Group AG (2.52K shares), and MORGAN STANLEY (649 shares).
This table shows the top 15 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.